Jubilant Pharmova reports significant increase in Q1 net profit to Rs 481.8 crore
New Delhi: Jubilant Pharmova Ltd has announced a significant increase in its consolidated net profit to Rs 481.8 crore. The net profit was boosted by gain on sale on investment in associate firm SOFIE Biosciences Inc USA.
According to a regulatory filing by Jubilant Pharmova, the company had reported a consolidated net profit of Rs 6 crore in the previous year
Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is engaged in Radiopharma, Allergy Immunotherapy, CDMO of Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses. With a network of 46 radio-pharmacies in the US, Jubilant’s Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services. Its other businesses such as Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Nonsterile products and Generics (Solid Dosage Formulations) caters to major regulated markets (USA, EU and other geographies) through multiple manufacturing facilities.
The CRDMO segment (through Jubilant Biosys) provides collaborative research and partnership for Drug Discovery through two research centers in India. The company is also involved in the manufacturing of Active Pharmaceutical Products (API) through a US FDA approved facility in Nanjangud, Karnataka. Jubilant Therapeutics (JTI) invested for in-house Proprietary Novel Drugs business and is a biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders.
